Citi starts ArriVent stock with buy rating citing promising lung cancer drug By Investing.com

Tuesday, Citi initiated coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $30.00. The firm’s analyst highlighted the potential of ArriVent’s drug candidate furmonertinib (furmo) in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

According to the analyst, furmonertinib distinguishes itself in the competitive landscape for EGFR exon 20 NSCLC treatments. This is despite the anticipation of amivantamab combined with chemotherapy becoming the new standard of care (SoC) in the first line (1L) treatment following the PAPILLON study’s success. The analyst believes furmonertinib could have a more competitive profile as a monotherapy.

The confidence in furmonertinib is based on several factors: its oral route of administration, remarkable activity in the central nervous system (CNS), a superior safety profile, and similar efficacy as a single agent compared to other treatments. The analyst also noted that furmonertinib might benefit from a first-to-market advantage, as Phase 3 results are expected in 2025, earlier than its oral tyrosine kinase inhibitor (TKI) competitors.

ArriVent is also exploring the use of furmonertinib for NSCLC EGFR PACC mutations, a market segment with less competition and significant potential, representing approximately 12% of the total EGFR market. The first human data for this application are anticipated to be released in 2024.

The analyst concluded the initiation report by describing the Buy rating as “High Risk,” reflecting the inherent uncertainties and speculative nature of investing in biopharmaceutical companies with drug candidates in development stages.

InvestingPro Insights

As Citi analysts express optimism about ArriVent BioPharma’s (NASDAQ:AVBP) furmonertinib, InvestingPro data provides additional context for investors considering the stock. Despite the promising outlook for furmonertinib, ArriVent’s financial metrics suggest caution. With a negative P/E ratio of -12.82 for the last twelve months as of Q3 2023, and an operating income of -61.91M USD in the same period, the company’s profitability remains a challenge.

InvestingPro Tips highlight that ArriVent holds more cash than debt, indicating a solid liquidity position, and its liquid assets exceed short-term obligations, providing some financial stability in the near term. However, the stock is currently in overbought territory according to the RSI, and ArriVent has weak gross profit margins, which could impact future earnings potential. Notably, the company has not been profitable over the last twelve months and does not pay a dividend to shareholders, which might deter income-focused investors.

For those interested in a deeper dive into ArriVent’s financials and future outlook, InvestingPro offers additional tips for a comprehensive analysis. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription and access more InvestingPro Tips, which currently list six additional insights for ArriVent BioPharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.